Email this article Hormonal therapy and chemotherapy in patients with hormone-sensitive prostate cancer
- Authors: Gafanov R.A.1
-
Affiliations:
- FSBI “Russian Scientific Center of Radiology” of Russian Ministry of Health
- Issue: Vol 12, No 1 (2016)
- Pages: 63-68
- Section: DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. PROSTATE CANCER
- Published: 30.03.2016
- URL: https://oncourology.abvpress.ru/oncur/article/view/503
- DOI: https://doi.org/10.17650/1726-9776-2016-12-1-63-68
- ID: 503
Cite item
Abstract
Prostate cancer is the most common men`s cancer in men in developed world and the second cause of death in this population. This review focuses on management of advanced castration resistant prostate cancer (CRPC) has been rapidly changing and is still evolving. In the last years, there has been an increasing knowledge of prostate cancer biology. New therapeutic agents and approaches have been evaluated demonstrating benefits in survival and quality of life in patients with metastatic prostate cancer.
Keywords
About the authors
R. A. Gafanov
FSBI “Russian Scientific Center of Radiology” of Russian Ministry of Health
Author for correspondence.
Email: docgra@mail.ru
86, Profsoyuznaya St., Moscow, 117997 Russian Federation
References
Supplementary files
